Biogen Reports Top-Line Results from Phase 3 Study Evaluating Natalizumab in Secondary Progressive MS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/16/2026

1. SPY
2. USO
3. NVDA
4. QQQ
5. INTC
6. ON
7. BETR
8. JPM
9. LEN
10. TLT

Go back to Biogen Reports Top-Line Results from Phase 3 Study Evaluating Natalizumab in Secondary Progressive MS
BIOGEN IDEC Inc. (NASDAQ: BIIB) Delayed: 216.01 -0.16 (0.07%)
Previous Close $216.17    52 Week High $333.65 
Open $216.41    52 Week Low $223.02 
Day High $218.29    P/E 27.66 
Day Low $214.81    EPS $7.81 
Volume 606,473